4,5-Dihydroxy-9,10-dioxo-4a,9,9a,10-tetrahydroanthracene-2-carboxylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: 4,5-Dihydroxy-9,10-dioxo-4a,9,9a,10-tetrahydroanthracene-2-carboxylic acid
• 英文别名: 4,5-dihydroxy-9,10-dioxo-4a,9a-dihydroanthracene-2-carboxylic acid
• 化学式: C₁₅H₁₀O₆
• 分子量: 286.24
• InChiKey: HHQNGUQUHZYDEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  112
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Compositions and methods for the prevention and treatment of circulatory conditions
  申请人：Lau T. David

  公开号：US20070037756A1

  公开（公告）日：2007-02-15

  The present invention relates to compositions and the prevention and treatment of circulatory conditions. In one embodiment, the present invention contemplates a compositions comprising anti-platelet aggregating activity. In another embodiment, the present invention contemplates methods to prevent or treat vascular or cardiovascular diseases. In another embodiment, the present invention relates to a method to prevent or treat cardiovascular disease by administering a glycerol saccharide derivative, an arylpolyphenol, a saccharide substituted with an arylpolyphenol, or a steroid substituted with an arylpolyphenol capable of reducing platelet aggregation. In one embodiment, the invention relates to a method of using the compounds capable of reducing platelet aggregation in order to prevent the recurrence of a heart attack by administration of the compounds to a subject after the subject has experienced a heart attack.

  本发明涉及组合物及其在循环疾病的预防和治疗中的应用。在一种实施例中，本发明涉及一种包含抗血小板聚集活性的组合物。在另一种实施例中，本发明涉及预防或治疗血管或心血管疾病的方法。在另一种实施例中，本发明涉及通过给予一种能够减少血小板聚集的甘油糖衍生物、芳基多酚、被芳基多酚取代的糖或被芳基多酚取代的类固醇来预防或治疗心血管疾病的方法。在一种实施例中，本发明涉及使用能够减少血小板聚集的化合物的方法，以通过给予化合物来预防心脏病发作的再次发生，该化合物在主体经历心脏病发作后给予。
• PHARMACEUTICAL COMPOSITIONS OF RHEIN OR DIACEREIN
  申请人：Wockhardt Limited

  公开号：EP2207532B1

  公开（公告）日：2012-08-29
• ORAL LIQUID COMPOSITIONS OF RHEIN OR DIACEREIN
  申请人：Verma Himanshu

  公开号：US20110166225A1

  公开（公告）日：2011-07-07

  The invention relates to liquid pharmaceutical compositions for oral administration comprising rhein or diacerein, or salts or esters or prodrugs thereof and processes for preparing such compositions.
• US9119819B2
  申请人：——

  公开号：US9119819B2

  公开（公告）日：2015-09-01
• [EN] PHARMACEUTICAL COMPOSITIONS OF RHEIN OR DIACEREIN<br/>[FR] COMPOSITIONS PHARMACEUTIQUES DE RHÉINE OU DE DIACÉRÉINE
  申请人：WOCKHARDT RESEARCH CENTER

  公开号：WO2009040702A2

  公开（公告）日：2009-04-02

  The invention relates to pharmaceutical compositions of rhein or diacerein, or salts or esters or prodrugs thereof which are bioequivalent to a 50 mg diacerein formulation marketed under the trade name Art 50®. The compositions exhibit no variability in fed and fasted state conditions. The compositions also result in significant reduction in side effects such as, soft stools as compared to Art 50®. The invention also relates to the methods for preparing such compositions.